scholarly journals IVUS PREDICTORS FOR DRUG ELUTING BALLOON FAILURE IN THE TREATMENT OF IN–STENT RESTENOSIS

2013 ◽  
Vol 61 (10) ◽  
pp. E1792
Author(s):  
Sung Yun Lee ◽  
Sang–Wook Kim ◽  
Jin Bae Lee ◽  
Eun–Seok Shin ◽  
Joon Hyung Doh ◽  
...  
Keyword(s):  
Stent Restenosis ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

Drug-eluting Balloons in Coronary Artery Disease – Current and Future Perspectives

2012 ◽  
Vol 8 (1) ◽  
pp. 56 ◽  
Author(s):  
Anouar Belkacemi ◽  
Pierfrancesco Agostoni ◽  
Michiel Voskuil ◽  
Pieter Doevendans ◽  
Pieter Stella ◽  
...  
Keyword(s):  
Small Vessel Disease ◽  
Percutaneous Treatment ◽  
Added Value ◽  
High Concentration ◽  
Diffuse Disease ◽  
Stent Restenosis ◽  
Alternative Treatment Option ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

Percutaneous treatment of complex coronary lesions, such as small-vessel disease, diabetes and long diffuse disease, remain hampered by suboptimal results, even with the use of drug-eluting stents (DES). The paclitaxel drug-eluting balloon (DEB) is an interesting emerging device that optimises clinical outcomes in these specific lesions. The DEB may become a viable alternative treatment option for the inhibition of coronary restenosis and subsequent revascularisation, as it allows local release of a high-concentration antirestenotic drug, paclitaxel, into the coronary vessel without using a metal scaffold or durable polymers. Several studies have already shown promising and consistent results in the treatment of in-stent restenosis. The DEB has demonstrated its added value compared with certain DES. Inspired by these results, an increasing number of studies have been started in different coronary lesion subsets to explore the value of the DEB in a broader range of lesions. It will be interesting to see whether the DEB will find more indications beyond in-stent restenosis treatment. Moreover, will all DEBs offer the same added value, or will there be differences in efficacy among the DEBs produced by the various manufacturers? As was the case in the development of DES, now the puzzle pieces have to be put together for DEB.

scholarly journals Efficacy of Drug-Eluting Balloon in the Treatment of Ostial Left Anterior Descending Artery In-Stent Restenosis

2014 ◽  
Vol 22 (2) ◽  
pp. 183-187
Author(s):  
Guy Fernando de Almeida Prado ◽  
Cristiano Guedes Bezerral ◽  
Gustavo Martins Pereira Alves ◽  
Marcio Augusto Meirelles Truffa ◽  
Expedito Eustaquio Ribeiro da Silva ◽  
...  
Keyword(s):  
Left Anterior Descending Artery ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

scholarly journals Drug-eluting balloon treatment in femoropopliteal in-stent restenosis of different lengths

2020 ◽  
Vol 28 (3) ◽  
pp. 460-466
Author(s):  
Berkan Özpak
Keyword(s):  
Stent Restenosis ◽  
Significant Difference ◽  
Stent Length ◽  
Drug Eluting ◽  
Group 3 ◽  
Group 2 ◽  
Drug Eluting Balloon ◽  
One Year ◽  
In Stent Restenosis ◽  
Group 1

Background: In this study, we present one-year results of drug-eluting balloon treatment of femoropopliteal in-stent restenosis. Methods: A total of 62 patients (48 males, 14 females; mean age 64.2±9.1 years; range, 54 to 81 years) who underwent drug-eluting balloon stenting for femoropopliteal in-stent restenosis between August 2013 and October 2017 were included in the study. The patients were classified into three groups based on the narrowing length of stenosis in the stents. Group/Class 1 (n=17): narrowing <1/2 of the stent length; Group/Class 2 (n=22): narrowing >1/2 of the stent length, not totally occluded; and Group/Class 3 (n=23): totally occluded. In-stent restenosis was treated with drug-eluting balloon treatment. Results: There was a significant difference among all classes in terms of in-stent restenosis. The length of stenosis was a predictor for in-stent restenosis. The mean stent length was 107.7±24.6 mm in Group 1, 164.6±17.9 mm in Group 2, and 180±19.3 mm in Group 3. For non-occluded in-stent restenosis, restenosis rate at one year after balloon angioplasty was 47.1% in Group 1, 86.4% in Group 2, and 95.7% in Group 3. Femoropopliteal bypass was performed in five patients in whom treatment failed. None of the patients required amputation. Conclusion: The length of in-stent restenosis in the femoropopliteal arterial stents is an important predictor for recurrent stenosis, when re-flow is achieved with drug-eluting balloons.

Abstract 340: Drug-Eluting Balloon Versus Everolimus-Eluting Stent for Restenosis in a Bare-Metal Stent: A Meta-Analysis of Randomized Trials

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Akintunde M Akinjero ◽  
Oluwole Adegbala ◽  
Tomi Akinyemiju
Keyword(s):  
Publication Bias ◽  
Meta Analysis ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Binary Restenosis ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

Background: In-stent restenosis accounts for major morbidity and mortality among patients treated with Bare-Metal Stents (BMS). Early efforts to treat BMS in-stent restenosis with plain balloon angioplasty and first generation drug eluting stents (DES) have been ineffective, leaving drug-eluting balloon (DEB) and second generation DES, such as everolimus eluting stents (EES), as the only remaining options. For BMS in-stent restenosis, studies performed so far have yielded conflicting results, while prior meta-analyses have been influenced by inclusion of observational studies. This is the first meta-analysis to compare EES versus DEB using results from only randomized controlled trials (RCTs). Methods: A systematic search of PUBMED and EMBASE databases was conducted from first available date to August, 2016 for RCTs comparing DEB with EES. Two reviewers evaluated studies for eligibility and extracted data with binary restenosis rate as the main endpoint. We identified 901 unique citations. Odds ratios were pooled using random-effects modeling. Funnel plots were used to assess publication bias. Heterogeneity was assessed using I 2 statistic. All analysis were performed using Review Manager (RevMan) version 5.3 (Cochrane Collaboration, 2014). Results: Three RCTs met study eligibility criteria, with 684 patients and a mean follow-up of 9.5 months. There were 184 and 185 patients in the EES and DEB arms respectively. In pooled analyses, EES was not superior to DEB in binary restenosis rates (pooled odds ratio: 0.76; 95% confidence interval: 0.25-2.32; P=0.14). Heterogeneity was minimal (I 2 = 49%), and the funnel plot did not suggest publication bias. Conclusion: In patients with BMS in-stent restenosis, there were no significant differences in binary restenosis rates between EES and DEB. Our results can enhance physician decision-making regarding choice of revascularization tool in this patient population.

Drug-Eluting Balloon for Treatment of In-Stent Restenosis After Carotid Artery Stenting: Preliminary Report

2012 ◽  
Vol 19 (6) ◽  
pp. 734-742 ◽  
Author(s):  
Piero Montorsi ◽  
Stefano Galli ◽  
Paolo M. Ravagnani ◽  
Daniela Trabattoni ◽  
Franco Fabbiocchi ◽  
...  
Keyword(s):  
Carotid Artery ◽  
Carotid Artery Stenting ◽  
Preliminary Report ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis
Sign in / Sign up

Export Citation Format

Share Document